Viawealth LLC Sells 4,357 Shares of GSK plc (NYSE:GSK)

Viawealth LLC lowered its holdings in GSK plc (NYSE:GSK) by 23.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 14,490 shares of the pharmaceutical company’s stock after selling 4,357 shares during the quarter. Viawealth LLC’s holdings in GSK were worth $490,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in the business. FMR LLC grew its holdings in GSK by 8.3% during the 3rd quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock worth $1,185,885,000 after acquiring an additional 2,224,345 shares during the last quarter. Primecap Management Co. CA lifted its position in shares of GSK by 70.1% during the fourth quarter. Primecap Management Co. CA now owns 25,261,660 shares of the pharmaceutical company’s stock worth $854,349,000 after purchasing an additional 10,407,905 shares in the last quarter. Fisher Asset Management LLC increased its holdings in shares of GSK by 1.4% in the fourth quarter. Fisher Asset Management LLC now owns 18,836,797 shares of the pharmaceutical company’s stock valued at $637,061,000 after purchasing an additional 259,867 shares in the last quarter. Mondrian Investment Partners LTD raised its position in GSK by 17.6% in the 4th quarter. Mondrian Investment Partners LTD now owns 5,838,384 shares of the pharmaceutical company’s stock worth $205,920,000 after purchasing an additional 874,004 shares during the last quarter. Finally, Equity Investment Corp lifted its holdings in GSK by 13.3% during the 4th quarter. Equity Investment Corp now owns 3,962,581 shares of the pharmaceutical company’s stock worth $134,014,000 after buying an additional 466,327 shares in the last quarter. Institutional investors own 15.74% of the company’s stock.

GSK Trading Down 2.1 %

NYSE GSK opened at $39.53 on Thursday. GSK plc has a 12 month low of $31.72 and a 12 month high of $45.93. The stock has a 50-day simple moving average of $36.42 and a 200 day simple moving average of $36.98. The company has a current ratio of 0.78, a quick ratio of 0.52 and a debt-to-equity ratio of 1.12. The company has a market capitalization of $81.81 billion, a PE ratio of 24.86, a P/E/G ratio of 1.12 and a beta of 0.58.

GSK (NYSE:GSK) last announced its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. Research analysts forecast that GSK plc will post 4.14 EPS for the current year.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be given a dividend of $0.3932 per share. This represents a $1.57 dividend on an annualized basis and a dividend yield of 3.98%. This is a boost from GSK’s previous quarterly dividend of $0.39. The ex-dividend date is Friday, February 21st. GSK’s dividend payout ratio (DPR) is currently 98.74%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on GSK shares. StockNews.com raised GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 7th. Morgan Stanley initiated coverage on GSK in a research report on Wednesday, February 12th. They issued an “equal weight” rating for the company. Seven research analysts have rated the stock with a hold rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.